Get started
Author

Sophie Cereja

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases
2008 · Jean-Jacques Kiladjian, Francisco Cervantes, et al. · Blood · 356
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial
2025 · Aurore Perrot, Cyrille Touzeau, et al. · Blood · 40
Evolving characteristics and outcome of secondary acute promyelocytic leukemia ( APL ): A prospective analysis by the F rench‐ B elgian‐ S wiss APL group
2015 · Thorsten Braun, Sophie Cereja, et al. · Cancer · 18
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2019 · Xavier Leleu, Guillemette Fouquet, et al. · Clinical Cancer Research · 15
Light Chain Escape in Multiple Myeloma
2018 · Thomas Dejoie, Guillemette Fouquet, et al. · Blood · 11
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
2015 · Xavier Leleu, Lionel Karlin, et al. · Blood · 10
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A
2018 · C. Kelaidi, T. Braun, et al. · Leukemia Research · 6
Posterior reversible encephalopathy syndrome (PRES) and myeloma
2023 · Ricardos Ghanem, Sylvie Glaisner, et al. · Leukemia Research Reports · 3
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
2017 · Xavier Leleu, Guillemette Fouquet, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotin
2023 · L. Veleanu, B. Tesson, et al. · Hematological Oncology · 2
PDF
Filgrastim-induced recurrent macroscopic hematuria in a patient with DNAJB9 positive fibrillary glomerulonephritis
2022 · Anne-Laure Faucon, Sophie Cereja, et al. · Journal of Nephrology · 2
Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?
2010 · Sophie Cereja, Sabine Brechignac, et al. · Blood · 2
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
2021 · Arthur Bobin, Maéva Kyheng, et al. · Leukemia · 1
Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA)
2014 · Charikleia Kelaidi, Thorsten Braun, et al. · Blood · 1
Rituximab, Fludarabine and Alkylating Agents in Peripheral Neuropathies Related to IgM Monoclonal Gammopathy with Autoantibody Activity against Myelin-Associated-Glycoprotein : a Retrospective Study of 15 Patients.
2009 · Lionel Karlin, Bertrand Arnulf, et al. · Blood · 1
P1166: Brigatinib in Patients With Alk-positive Anaplastic Large Cell Lymphoma Who Have Failed Brentuximab Vedotin
2023 · Layla Veleanu, Bruno Tesson, et al. · HemaSphere
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
PDF
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
IFM2012-03
2016 · Xavier Leleu, Guillemette Fouquet, et al. · Blood
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL
2015 · Leleu, Xavier, Karlin, Lionel, et al. · HAL
210 Should immunosuppressive therapy (1ST) be used more often in lower risk MDS?
2011 · S. Cereja, S. Brechignac, et al. · Leukemia Research
Works count: 27
Citation count: 471
H-index: 6
I10-index: 6
Year
Topic
Type